30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Biomet

(for fiscal 2Q14, ended 11/30/13)

$825.7MM, +5% (U.S. $493.1MM, +5%; Europe $211.8MM, +6%; International $120.8MM, +7%)

  • Hips $167.7MM, +4% (U.S. +3%)
  • Knees $264.0MM, +8% (U.S. +8%)
  • Sports Med/Extremities/Trauma (S.E.T.) $160.3MM, +6% (U.S. +6%)
  • Spine, Bone Healing & Microfixation $104.9MM, +2% (U.S. -2%)
  • Dental $70.5MM, +5% (U.S. +10%)
  • Cement, Biologics & Other $58.3MM, +3% (U.S. -2%)



  • Overall growth attributed to improvement in Europe, combination of improving market conditions, share gains, large distributor orders
  • Specifically, Spain market showing significant improvement across all segments
  • Based on customer/distributor conversations, market stable during quarter, U.S. volumes appear to be improving
  • Worldwide hip/knee pricing decreased at low single-digit rate



  • Strong demand for Taperloc Complete and Echo lines, Arcos femoral revision system
  • Launched G7 multi-bearing acetabular system in U.S. and Japan; rollout will continue into FY15
  • G7’s implant/instrument color coding system is designed to simplify procedures in the OR; when used with Orthosize 2D or Signature 3D pre-op planning, can help reduce the need for a large number of instruments/trays



  • Claims #1-#2 position in U.S. revision knees
  • Ran new Oxford knee direct-to-consumer ad campaigns in select U.S. markets
  • Confirmed AAOS debut of XP bi-cruciate preserving arthroplasty device, an addition to Vanguard portfolio; launch slated for 2H14



  • Growth primarily from extremities, such as Comprehensive Shoulder, ExploR Modular Radial Head; segment in 24th consecutive quarter of double-digit increases
  • Launched ToggleLoc with ZipLoop line extension, with retrograde zipping and revision implant
  • Launching Signature Personalized Patient Care Guide System in FY3Q, to support intra-op positioning of glenoid components
  • Commenced global launch of DVR Crosslock ePAK distal radius plate system: pre-sterilized disposable kit comprising implant + instruments; has now been used in Australia, Europe, Latin America, South America, U.S.
  • Initiated U.S. launch of OsseoTi porous metal osteotomy wedges as an alternative to allograft wedges for foot/ankle


Spine, Bone Healing & Microfixation

  • Closed Lanx aquisition
  • Strong adoption of Lineum and MaxAn cervical products supported growth, as did Cellentra stem cell product and sales of the acquired Timberline Lateral System
  • Received approval to enroll 50 patients in IDE study of SpinalPak stimulator for early treatment of degenerative disc disease


Cement, Biologics & Other

  • Continued strong Japan market acceptance for Cobalt bone cement
  • Investments in biologic programs includes NStride APS autologous therapy for early-stage OA, a potential substitute for hyaluronic acid; U.S. pilot study to commence in 2H14